Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)
Completed
Baxter Healthcare Corporation
Phase 2
2016-06-01
The purpose of this study is to evaluate the efficacy and safety of HyQvia (Immunoglobulin
10% with recombinant hyaluronidase) with conventional subcutaneous immunoglobulin treatment
in patients with Multifocal Motor Neuropathy (MMN).
Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)
Completed
Johannes Jakobsen
Phase 2
2016-06-01
The purpose of this study is to evaluate the efficacy and safety of HyQvia (Immunoglobulin
10% with recombinant hyaluronidase) with conventional subcutaneous immunoglobulin treatment
in patients with Multifocal Motor Neuropathy (MMN).
IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
Completed
Shire
Phase 4
2016-11-11
Most immunodeficiencies are related to severe immunoglobulin deficiencies which require
lifelong replacement therapy with immunoglobulin G (IgG) to reduce the incidence and severity
of infections. IgG can be administered intravenously (IGIV) every 21 or 28 days or
subcutaneously every week or every other week (IGSC) for subjects who do not tolerate IV
infusions or have difficulties with venous access. No head-to-head data are available to
directly compare HyQvia with conventional SCIG. However, SCIG is indicated for administration
frequencies from daily up to every other week dosing while HyQvia is indicated for infusion
frequencies every 2-4 weeks. This study is designed to assess the IgG trough level after
switching from standard SCIG to every other week HyQvia and HyQvia every 3-4 weeks
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
